成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天
Hi!歡迎來(lái)到ChemicalBook
登錄
注冊(cè)
熱線電話:400-158-6606
行業(yè)精選
我的ChemicalBook
發(fā)布產(chǎn)品
產(chǎn)品管理
發(fā)布供應(yīng)信息
黃金產(chǎn)品設(shè)置
大貨產(chǎn)品設(shè)置
直通車(chē)產(chǎn)品設(shè)置
∨
發(fā)布供應(yīng)信息
產(chǎn)品
求購(gòu)信息
供應(yīng)信息
化工站點(diǎn)
結(jié)構(gòu)式搜索
采購(gòu)清單
網(wǎng)站主頁(yè)
化工產(chǎn)品目錄
原料藥
解熱鎮(zhèn)痛藥
非甾抗炎藥
羅非昔布
羅非考昔
羅非考昔|T1185|TargetMol
價(jià)格
¥
311
¥
565
¥
410
包裝
50mg
200mg
100mg
最小起訂量
1mg
發(fā)貨地
上海
更新日期
2024-12-02
QQ交談
微信洽談
產(chǎn)品詳情
中文名稱:
羅非考昔
英文名稱:
Rofecoxib
CAS:
162011-90-7
品牌:
TargetMol
產(chǎn)地:
美國(guó)
保存條件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
純度規(guī)格:
99.94%
產(chǎn)品類別:
抑制劑
貨號(hào):
T1185
2024-12-02
羅非考昔
Rofecoxib
50mg/311RMB;200mg/565RMB;100mg/410RMB
311
TargetMol
美國(guó)
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
99.94%
抑制劑
Product Introduction
Bioactivity
名稱
Rofecoxib
描述
Rofecoxib (MK 966) binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with anti-inflammatory, antipyretic and analgesic properties and potential antineoplastic properties. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.
細(xì)胞實(shí)驗(yàn)
The human osteosarcoma cell line has been shown to selectively express COX-2 by reverse transcription-polymerase chain reaction and immunoblot analysis, whereas undifferentiated human lymphoma U937 cells selectively express COX-1. The production of PGE2 by these cells after arachidonic acid challenge is used as an index of cellular COX-2 and COX-1 activity, respectively. Rofecoxib is preincubated for 5 to 15 minutes with the cells under serum-free conditions [Hanks' balanced salt solution (HBSS)] before a 10-minutes stimulation with 10 μM arachidonic acid and measurement of PGE2 production. COX activity in each cell line is defined as the difference in PGE2 concentrations in samples incubated in the presence or absence of arachidonic acid.(Only for Reference)
激酶實(shí)驗(yàn)
In vitro biochemical and pharmacological assaysinhibition studies with recombinant human COX-1 and COX-2: Microsomal preparations of recombinant human COX-1 and COX-2 are prepared from a vaccinia virus-COS-7 cell expression system. Recombinant human COX-1 and COX-2 are expressed in baculovirus-Sf9 cells, and enzymes are purified. Enzymatic activity is monitored continuously by either a fluorescence assay measuring the appearance of the oxidized form of the reducing agent cosubstrate homovanillic acid or by oxygen consumption. The HPLC assay for the assessment of inhibition of purified COX-1 by Rofecoxib with 0.1 μM arachidonic acid substrate concentration, the determination of the stoichiometry of the complex between COX-2 and Rofecoxib, the dissociation rate constant of the enzyme-inhibitor complex by recovery of enzymatic activity, and the recovery of intact Rofecoxib from that complex are all performed as described previously. The solvent system for the HPLC analysis of Rofecoxib is 15:85 MeOH/aqueous potassium phosphate (1 g/liter), with elution by a linear gradient of 15 to 75% MeOH over 25 minutes with detection at 275 nm on a Novapak C18 column.
體外活性
Rofecoxib inhibits the COX-2-dependent production of PGE2 in human osteosarcoma cells with an IC50 of 26 nM. Rofecoxib is a time-dependent inhibitor of purified human recombinant COX-2 with an IC50 of 0.34 μM. Rofecoxib causes inhibition of purified human COX-1 in a non-time-dependent manner. In a human whole blood assay, Rofecoxib selectively inhibits lipopolysaccharide-induced, COX-2-derived PGE2 synthesis with an IC50 value of 0.53 μM compared with an IC50 value of 18.8 μM for the inhibition of COX-1-derived thromboxane B2 synthesis after blood coagulation. [1] Rofecoxib moderately inhibits phenacetin O-deethylation with an IC50 of 23 μM. And a 30-minute preincubation with microsomes and NADPH considerably increases the inhibitory effect of Rofecoxib with an IC50 of 4.2 μM. Inactivation of CYP1A2 by rofecoxib requires NADPH, and is characterized by a K i of 4.8 μM. [2]
體內(nèi)活性
Rofecoxib potently inhibits carrageenan-induced paw edema, carrageenan-induced paw hyperalgesia, lipopolysaccharide-induced pyresis with IC50 of 1.5 mg/kg, 1.0 mg/kg and 0.24 mg/kg, respectively. Rofecoxib also blocks adjuvant-induced arthritis with an IC50 of 0.74 mg/kg/day. Rofecoxib also has a protective effect on adjuvant-induced destruction of cartilage and bone structures in rats. [1] Oral administration of rofecoxib decreases portal pressure in rats that are treated with CCl4 for 8 weeks. In addition, rofecoxib administration reduces the number of activated HSCs and to downregulate hepatic protein levels of three detected types of collagen, laminin, VEGF and CTGF in CCl4-treated rats. [3]
存儲(chǔ)條件
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度
DMSO : 50 mg/mL (159.05 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字
inhibit | MK 0966 | Cyclooxygenase | MK0966 | Inhibitor | MK966 | Rofecoxib | COX | MK-966
相關(guān)產(chǎn)品
Revaprazan hydrochloride | Ibuprofen | Paradol | Glafenine | trans-Cinnamaldehyde | Acetaminophen | Diclofenac Potassium | Indomethacin sodium hydrate | Salicylamide | Salicylic acid | Bismuth Subsalicylate | Diclofenac sodium
相關(guān)庫(kù)
抗癌上市藥物庫(kù) | 抗癌活性化合物庫(kù) | 抗衰老化合物庫(kù) | FDA 上市藥物庫(kù) | 藥物功能重定位化合物庫(kù)
關(guān)鍵字:
羅非昔布|||羅非考昔|||MK-0966|||MK 966|TargetMol
公司簡(jiǎn)介
上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起,為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部,化學(xué)事業(yè)部,生物事業(yè)部和新材料部。 從虛擬篩選到實(shí)體化合物分子供應(yīng);從商業(yè)化產(chǎn)品銷(xiāo)售到個(gè)性化定制合成;從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選,從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化,我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。 經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘,我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商,為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩
成立日期
2013-04-18
(12年)
注冊(cè)資本
566.2651萬(wàn)人民幣
員工人數(shù)
100-500人
年?duì)I業(yè)額
¥ 1億以上
主營(yíng)行業(yè)
化學(xué)試劑,生物活性小分子
經(jīng)營(yíng)模式
貿(mào)易,試劑,定制,服務(wù)
TargetMol中國(guó)(陶術(shù)生物)
VIP
12年
公司成立:
12年
注冊(cè)資本:
566.2651萬(wàn)人民幣
企業(yè)類型:
有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品:
小分子抑制劑,藥物篩選化合物庫(kù),天然產(chǎn)物,活性分子化合物等
公司地址:
上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓
進(jìn)入店鋪
詢盤(pán)
店內(nèi)推薦
化合物 m-PEG3-OH|T15860|TargetMol
¥913
化合物 H-Ala-OEt.HCl|T67576|TargetMol
¥143
化合物 Fluvoxketone|T65390|TargetMol
¥333
羅非考昔|T1185|TargetMol相關(guān)廠家報(bào)價(jià)
更多
產(chǎn)品名稱
價(jià)格
公司名稱
報(bào)價(jià)日期
羅非昔布
詢價(jià)
VIP
5年
武漢華玖醫(yī)藥科技有限公司
2024-12-26
羅非昔布
詢價(jià)
VIP
7年
麻城市進(jìn)鑫生物科技有限公司
2024-12-24
羅非昔布;162011-90-7
詢價(jià)
VIP
2年
寶雞締都醫(yī)藥化工有限公司
2024-12-09
aladdin 阿拉丁 R408064 羅非昔布 162011-90-7 10mM in DMSO
¥450.90
VIP
1年
上海阿拉丁生化科技股份有限公司
2024-11-29
aladdin 阿拉丁 R126597 羅非昔布 162011-90-7 ≥98%
¥481.90
VIP
13年
上海阿拉丁生化科技股份有限公司
2024-10-31
Rofecoxib (Vioxx)
詢價(jià)
南京百鑫德諾生物科技有限公司
2024-09-26
羅非昔布
詢價(jià)
武漢鵬胤藥業(yè)有限公司
2020-09-12
羅非昔布 162011-90-7 Rofecoxib貨到付款支持阿里淘寶交易微興電話180-6266-6868
詢價(jià)
重慶賽浦那斯化工有限公司
2019-01-05
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買(mǎi)數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè)
|
企業(yè)會(huì)員服務(wù)
|
廣告業(yè)務(wù)
|
聯(lián)系我們
|
舊版入口
|
中文MSDS
|
CAS Index
|
常用化學(xué)品CAS列表
|
化工產(chǎn)品目錄
|
新產(chǎn)品列表
|
投訴中心
Copyright ? 2008 ChemicalBook
京ICP備07040585號(hào)
京公海網(wǎng)安備110108000080號(hào) All rights reserved.
400-158-6606
TargetMol中國(guó)(陶術(shù)生物)
聯(lián)系人:
邵小姐
電話:
021-021-33632979
手機(jī):
15002134094
郵箱:
marketing@targetmol.com
聯(lián)系商家時(shí)請(qǐng)?zhí)峒癱hemicalbook,有助于交易順利完成!
產(chǎn)品咨詢